Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

Logo-Geneoscopy-400
05/23/2022

Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test

READ MORE
Logo-Geneoscopy-400
05/23/2022

Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test

READ MORE
CareVet-Logo-New
05/19/2022

Best Places to Work 2022: CareVet caters to young professionals with its perks, flexibility

READ MORE
C4-logo-400
05/16/2022

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

READ MORE
wugen-logo-400
05/12/2022

Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

READ MORE
C4-logo-400
05/05/2022

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

READ MORE
C4-logo-400
04/08/2022

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

READ MORE
wugen-logo-400
04/07/2022

Wugen to Participate in Upcoming April Investor Conferences

READ MORE
wugen-logo-400
03/24/2022

Wugen to Present at the Innate Killer Summit 2022

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300